Evans, T. R. Jeffry
Dean, Emma
Molife, L. Rhoda
Lopez, Juanita
Ranson, Malcolm
El-Khouly, Fatima
Zubairi, Ishtiaq
Savulsky, Claudio
Reyderman, Larisa
Jia, Yan
Sweeting, Lorna
Greystoke, Alastair
Barriuso, Jorge
Kristeleit, Rebecca
Article History
Received: 31 May 2018
Revised: 6 December 2018
Accepted: 3 January 2019
First Online: 25 January 2019
Competing interests
: T.R.J.E.: honoraria from Bristol-Myers Squibb and Eisai; participated in speaker’s bureau for Bristol-Myers Squibb, Eisai and Celgene; paid consultancy from Bristol-Myers Squibb, Eisai, Celgene and Karus Therapeutics; received research funding from Astra Zeneca, Celgene, Eisai, GlaxoSmithKline, Roche, Ono, Bristol-Myers Squibb, Eli Lily, Basilea, Vertex, Merck, Daiichi Sankyo, Nutide, Sierra, Immunocore Verastem; expenses paid by Bristol-Myers Squibb; Subject Editor of the <i>British Journal of Cancer</i>. E.D.: research fees from The Christie NHS Foundation; employee of AstraZeneca with stock options; Independent Safety Physician for Theradex CRO; participated in advisory board for Aptus Clinical Limited. J.L.: paid consultancy for Merck and Eisai. M.R.: financial support from Eisai. C.S.: employee of Eisai. L.R.: employee of Eisai. Y.J.: employee of Eisai. The remaining authors declare no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki and guidelines of the International Conference for Harmonisation/Good Clinical Practice and was approved by a central research ethics committee in the UK. All patients provided written informed consent prior to undergoing any study-related procedure.